Five patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2037. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2037
Next term end
4
Patent families
When these terms end
Each bar runs from grant to computed term end. 2022 to 2037.20252028203120342037
3 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2037 · High confidence
Also notable
Ends Oct 2037 · High confidence
Also notable
Ends Apr 2037 · High confidence
Stable Multispecific Antibodies
US 11,560,437
The most cited patent in this portfolio, cited by 4 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Binding Molecules to CD38 and PD-L1
US 11,505,616
The earliest of the three still in force, granted 2022 and renewed since. Its term ends first, in 2037. A terminal disclaimer caps this term to an earlier patent's.
A Polypeptide Linker for Preparing Multispecific Antibodies
US 11,958,913
Granted 2024. Too new for citation comparison; protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 16, 2027The maintenance fee for A Polypeptide Linker for Preparing Multispecific Antibodies (US 11,958,913) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Binding Molecules to CD38 and PD-L1 | 2 in force | to Oct 2037 |
| Stable Multispecific Antibodies | 1 in force | to Oct 2037 |
| Bispecific Antibodies Targeting Egfr and HER2 | 1 in force | to Apr 2037 |
| A Polypeptide Linker for Preparing Multispecific Antibodies | 1 in force | to Apr 2037 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,528,877 | Binding Molecules to CD38 and PD-L1 In force · High confidence | In force | High confidence | |
| US 11,958,913 | A Polypeptide Linker for Preparing Multispecific Antibodies In force · High confidence | In force | High confidence | |
| US 12,054,550 | Bispecific Antibodies Targeting Egfr and HER2 In force · High confidence | In force | High confidence | |
| US 11,505,616 | Binding Molecules to CD38 and PD-L1 In force · High confidence | In force | High confidence | |
| US 11,560,437 | Stable Multispecific Antibodies In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 3 applications pending. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.